Navigation Links
Nuvelo Announces Preclinical Data for NU206 Demonstrating Potent Therapeutic Activity in Oral Mucositis Models
Date:4/14/2008

SAN CARLOS, Calif., April 14 /PRNewswire-FirstCall/ -- Nuvelo, Inc. (Nasdaq: NUVO) today announced preclinical data demonstrating the mechanism of action and the potent therapeutic activity of NU206 (R-spondin1) in chemotherapy or radiation-induced oral mucositis models. The data were presented in a poster session yesterday at the 2008 American Association for Cancer Research (AACR) Annual Meeting in San Diego, CA.

The study, conducted in mouse models of oral mucositis, showed that NU206 regenerated basal layer epithelial cells and accelerated cell repair by stimulating the Wnt pathway, a signaling pathway that is critical for cell growth and differentiation during homeostasis and pathogenesis.

"This study reinforces our belief that NU206 is a potent regenerative agent," said Dr. Ted W. Love, chairman and chief executive officer of Nuvelo. "We are on track to begin a Phase 1 trial with NU206 in the second quarter of this year, and are also assessing the therapeutic potential of other secreted proteins in the R-spondin family through our Wnt therapeutics program, which targets a range of indications where cell regeneration and differentiation are important to disease processes, including gastrointestinal disease, bone disorders, wound healing and cancer."

About NU206 and R-Spondin secreted proteins

NU206 (R-spondin1) is a recombinant, secreted protein that acts as a highly specific regulator of the gastrointestinal epithelial cell function as demonstrated in early animal studies. Preclinical studies suggest it can promote growth and repair in animal models of radiation or cancer chemotherapy induced gastrointestinal injury, as well as in animal models of inflammatory bowel disease.

The R-spondin (Rspo) fa
'/>"/>

SOURCE Nuvelo, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Nuvelo Re-Initiates SONOMA-3 Trial of Alfimeprase in Patients With Catheter Occlusion
2. Nuvelo Announces Alfimeprase SONOMA-2 Catheter Occlusion Data Presentation Webcast and Conference Call
3. Nuvelo Begins Phase 2 Trial and Receives Fast Track Status for Alfimeprase in Patients With Acute Ischemic Stroke
4. Nuvelo Initiates Phase 1 Clinical Trial of Thrombin Inhibitor, NU172
5. Nuvelo Announces Phase 2 SONOMA-3 Trial Did Not Meet Target Product Profile and Discontinues Alfimeprase Development
6. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
7. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
8. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
9. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
10. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
11. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/22/2014)... , July 22, 2014  Pressure ... "Company") and Parabase Genomics ("Parabase"), (together "the ... a strategic research and development agreement (the ... PBI will develop a front-end, sample preparation ... and newborn confirmatory testing process. The sample ...
(Date:7/22/2014)... July 22, 2014  NeuroSigma, Inc. (NeuroSigma), a ... commercialization of its non-invasive Monarch ™ eTNS™ ... disorders, today announced that enrollment has begun in a ... (eTNS) as adjunctive therapy for the treatment of Lennox-Gastaut ... at the Olive View-UCLA Medical Center in ...
(Date:7/22/2014)... , July 22, 2014 ... umfassenden Schutz von Pharmazeuten und Krankenpflegern ... Equashield ( http://www.equashield.com ), ... System Transfer Devices, CSTDs) für gefährliche Medikamente, ernannte ... und Hersteller von medizinischen Produkten, zu seinem ...
Breaking Medicine Technology:Pressure BioSciences to Develop Front-end Sample Preparation for Parabase Genomics' Targeted Next Generation Sequencing Testing Platform 2Pressure BioSciences to Develop Front-end Sample Preparation for Parabase Genomics' Targeted Next Generation Sequencing Testing Platform 3Pressure BioSciences to Develop Front-end Sample Preparation for Parabase Genomics' Targeted Next Generation Sequencing Testing Platform 4Enrollment Commences in NeuroSigma-Sponsored Pediatric Clinical Trial for the Treatment of Lennox-Gastaut Syndrome 2Enrollment Commences in NeuroSigma-Sponsored Pediatric Clinical Trial for the Treatment of Lennox-Gastaut Syndrome 3Enrollment Commences in NeuroSigma-Sponsored Pediatric Clinical Trial for the Treatment of Lennox-Gastaut Syndrome 4Enrollment Commences in NeuroSigma-Sponsored Pediatric Clinical Trial for the Treatment of Lennox-Gastaut Syndrome 5Equashield ernennt Medikus zu seinem exklusiven österreichischen Vertriebspartner für seine geschlossenen Arzneimitteltransfersysteme 2
... Turn the Tide on Antibiotic-Resistant InfectionsPRINCETON, N.J., March ... and the Plexus Institute (Plexus) today announce results ... Staphylococcus aureus (MRSA) prevention program that employed ... and behavioral change, to trigger significant reductions in ...
... the "NEXT" Study Also Showed Arzoxifene Significantly Suppressed ... with OsteoporosisATHENS, Greece, March 23 Eli Lilly ... new data showing arzoxifene, an investigational selective estrogen ... increasing bone mineral density (BMD) in the lumbar ...
Cached Medicine Technology:CDC Analysis Finds Unique Social and Behavior Intervention Helps Reduce MRSA Rates Up to 62% in Study Hospitals 2CDC Analysis Finds Unique Social and Behavior Intervention Helps Reduce MRSA Rates Up to 62% in Study Hospitals 3CDC Analysis Finds Unique Social and Behavior Intervention Helps Reduce MRSA Rates Up to 62% in Study Hospitals 4Phase III Trial Showed Investigational Compound Arzoxifene Was Superior to Evista(R) (raloxifene HCl) in Increasing BMD in Postmenopausal Women with Osteoporosis 2Phase III Trial Showed Investigational Compound Arzoxifene Was Superior to Evista(R) (raloxifene HCl) in Increasing BMD in Postmenopausal Women with Osteoporosis 3Phase III Trial Showed Investigational Compound Arzoxifene Was Superior to Evista(R) (raloxifene HCl) in Increasing BMD in Postmenopausal Women with Osteoporosis 4Phase III Trial Showed Investigational Compound Arzoxifene Was Superior to Evista(R) (raloxifene HCl) in Increasing BMD in Postmenopausal Women with Osteoporosis 5
(Date:7/22/2014)... (PRWEB) July 22, 2014 DocbookMD ... process of deploying one of the largest physician-centric mobile ... ( MHMD ) in Houston. , Created by Austin-based ... the DocbookMD application will be embedded into MHMD’s Accountable ... searched for the best technology to put this capability ...
(Date:7/22/2014)... (PRWEB) July 22, 2014 Dr. Dental is ... existing patients and new visitors in mind, one of the ... and visual layout that makes navigation very easy. Dr. Dental ... experience of going to the dentist affordable, convenient and fun, ... helpful new feature is an appointment scheduling system right on ...
(Date:7/22/2014)... 22, 2014 A Florida woman has ... that alleges the death of her husband was the ... thinner, Bernstein Liebhard LLP reports. According to her complaint, ... for the Southern District of Florida on June 23rd, ... suffered a subdural hemorrhage the following June. Despite emergency ...
(Date:7/22/2014)... Among women undergoing a minimally invasive hysterectomy using electric ... 10,000 women at the time of the procedure, according ... has been concern that this procedure, in which the ... the spread of undetected malignancies. , Despite the commercial ... estimates of the prevalence of malignancy at the time ...
(Date:7/22/2014)... July 22, 2014 Legislation backed ... Access to Local Pharmacies Act of 2014”) championing ... D would undermine the availability of lower cost ... $21 billion over the next 10 years, according ... by the Pharmaceutical Care Management Association (PCMA). , ...
Breaking Medicine News(10 mins):Health News:Memorial Hermann Physician Network Launches Physician Mobile Communication Solution Throughout Houston 2Health News:Memorial Hermann Physician Network Launches Physician Mobile Communication Solution Throughout Houston 3Health News:Memorial Hermann Physician Network Launches Physician Mobile Communication Solution Throughout Houston 4Health News:Dr. Dental Reveals Exciting New Website 2Health News:Xarelto Lawsuit Filed by Florida Woman Alleges Uncontrollable Bleeding Led to Husband’s Death, Bernstein Liebhard LLP Reports 2Health News:Xarelto Lawsuit Filed by Florida Woman Alleges Uncontrollable Bleeding Led to Husband’s Death, Bernstein Liebhard LLP Reports 3Health News:Study examines presence of uterine cancers at the time of hysterectomy using morcellation 2Health News:PCMA: New Study Finds H.R. 4577 to Cost $21 Billion Over 10 Years 2
... , ... ... ... ...
... Research (AADR) has announced David C. Johnsen, dean of the ... the 2010 AADR Jack Hein Public Service Award. This award ... Meeting & Exhibition in Washington, DC, March 3, 2010. ... Institutes of Health and the National Institute of Dental and ...
... American Association for Dental Research (AADR) has announced Irwin D. ... York, as the recipient of the inaugural 2010 AADR Distinguished ... Annual Meeting & Exhibition in Washington, DC, March 3, 2010. ... in 1946, and gave up his part-time private practice in ...
... study suggests , FRIDAY, Feb. 19 (HealthDay News) -- In ... have identified a defective signaling pathway that contributes to the ... thick, sticky mucus to build up in the lungs and ... lethal genetic diseases in children and young adults. , In ...
... ... ... ... ...
... ... in the Ambulatory EHR space , ... (PRWEB) February 19, 2010 -- CapSite™ has announced the release of the 2010 U.S. ... the Health Information Technology for Economic and Clinical Health (HITECH) component of the American Recovery ...
Cached Medicine News:Health News:Figure Skating Standards Foster Eating Disorders, Says Kimberly Dennis, M.D. 2Health News:Figure Skating Standards Foster Eating Disorders, Says Kimberly Dennis, M.D. 3Health News:Figure Skating Standards Foster Eating Disorders, Says Kimberly Dennis, M.D. 4Health News:Figure Skating Standards Foster Eating Disorders, Says Kimberly Dennis, M.D. 5Health News:Figure Skating Standards Foster Eating Disorders, Says Kimberly Dennis, M.D. 6Health News:Figure Skating Standards Foster Eating Disorders, Says Kimberly Dennis, M.D. 7Health News:Figure Skating Standards Foster Eating Disorders, Says Kimberly Dennis, M.D. 8Health News:Drug Improved Survival in Mice With Cystic Fibrosis 2Health News:Jim Huber to Serve as National Spokesman for 'Know Your Score: Fight Prostate Campaign' at Myrtle Beach Golf Holiday in August 2Health News:Jim Huber to Serve as National Spokesman for 'Know Your Score: Fight Prostate Campaign' at Myrtle Beach Golf Holiday in August 3Health News:Jim Huber to Serve as National Spokesman for 'Know Your Score: Fight Prostate Campaign' at Myrtle Beach Golf Holiday in August 4Health News:Jim Huber to Serve as National Spokesman for 'Know Your Score: Fight Prostate Campaign' at Myrtle Beach Golf Holiday in August 5Health News:Jim Huber to Serve as National Spokesman for 'Know Your Score: Fight Prostate Campaign' at Myrtle Beach Golf Holiday in August 6Health News:CapSite Announces Release of the 2010 U.S. Ambulatory EHR Study 2
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: